Update on immunosuppressive therapy.
Identifieur interne : 002717 ( Main/Exploration ); précédent : 002716; suivant : 002718Update on immunosuppressive therapy.
Auteurs : N G Singer [États-Unis] ; W J MccuneSource :
- Current opinion in rheumatology [ 1040-8711 ] ; 1998.
Descripteurs français
- KwdFr :
- Adulte, Arthrite juvénile (traitement médicamenteux), Association de médicaments, Azathioprine (effets indésirables), Azathioprine (usage thérapeutique), Chloro-2 désoxyadénosine (usage thérapeutique), Ciclosporine (usage thérapeutique), Cyclophosphamide (administration et posologie), Cyclophosphamide (usage thérapeutique), Enfant, Foie (), Foie (traumatismes), Granulomatose avec polyangéite (traitement médicamenteux), Humains, Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Immunosuppresseurs (administration et posologie), Immunosuppresseurs (effets indésirables), Immunosuppresseurs (usage thérapeutique), Lupus érythémateux disséminé (traitement médicamenteux), Lésion pulmonaire, Maladie de Behçet (traitement médicamenteux), Méthotrexate (administration et posologie), Méthotrexate (effets indésirables), Méthotrexate (usage thérapeutique), Pemphigoïde bénigne des muqueuses (traitement médicamenteux), Poumon (), Rétine (), Tacrolimus (usage thérapeutique), Thalidomide (usage thérapeutique).
- MESH :
- administration et posologie : Cyclophosphamide, Hydroxychloroquine, Immunosuppresseurs, Méthotrexate.
- effets indésirables : Azathioprine, Hydroxychloroquine, Immunosuppresseurs, Méthotrexate.
- traitement médicamenteux : Arthrite juvénile, Granulomatose avec polyangéite, Lupus érythémateux disséminé, Maladie de Behçet, Pemphigoïde bénigne des muqueuses.
- traumatismes : Foie.
- usage thérapeutique : Azathioprine, Chloro-2 désoxyadénosine, Ciclosporine, Cyclophosphamide, Hydroxychloroquine, Immunosuppresseurs, Méthotrexate, Tacrolimus, Thalidomide.
- Adulte, Association de médicaments, Enfant, Foie, Humains, Lésion pulmonaire, Poumon, Rétine.
English descriptors
- KwdEn :
- Adult, Arthritis, Juvenile (drug therapy), Azathioprine (adverse effects), Azathioprine (therapeutic use), Behcet Syndrome (drug therapy), Child, Cladribine (therapeutic use), Cyclophosphamide (administration & dosage), Cyclophosphamide (therapeutic use), Cyclosporine (therapeutic use), Drug Therapy, Combination, Granulomatosis with Polyangiitis (drug therapy), Humans, Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Liver (drug effects), Liver (injuries), Lung (drug effects), Lung Injury, Lupus Erythematosus, Systemic (drug therapy), Methotrexate (administration & dosage), Methotrexate (adverse effects), Methotrexate (therapeutic use), Pemphigoid, Benign Mucous Membrane (drug therapy), Retina (drug effects), Tacrolimus (therapeutic use), Thalidomide (therapeutic use).
- MESH :
- chemical , administration & dosage : Cyclophosphamide, Hydroxychloroquine, Immunosuppressive Agents, Methotrexate.
- chemical , adverse effects : Azathioprine, Hydroxychloroquine, Immunosuppressive Agents, Methotrexate.
- drug effects : Liver, Lung, Retina.
- drug therapy : Arthritis, Juvenile, Behcet Syndrome, Granulomatosis with Polyangiitis, Lupus Erythematosus, Systemic, Pemphigoid, Benign Mucous Membrane.
- injuries : Liver.
- chemical , therapeutic use : Azathioprine, Cladribine, Cyclophosphamide, Cyclosporine, Hydroxychloroquine, Immunosuppressive Agents, Methotrexate, Tacrolimus, Thalidomide.
- Adult, Child, Drug Therapy, Combination, Humans, Lung Injury.
Abstract
In this review we summarize selected articles that have been published about immunosuppressive agents in the past year. These studies fall into three major categories: 1) use of pulse cyclophosphamide in autoimmune diseases other than systemic lupus erythematosus; 2) use of newer immunosuppressive agents such as cyclosporine and FK506 in a variety of rheumatic diseases; and 3) toxicity.
DOI: 10.1097/00002281-199805000-00003
PubMed: 9608317
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000502
- to stream PubMed, to step Curation: 000502
- to stream PubMed, to step Checkpoint: 000472
- to stream Ncbi, to step Merge: 001179
- to stream Ncbi, to step Curation: 001179
- to stream Ncbi, to step Checkpoint: 001179
- to stream Main, to step Merge: 002755
- to stream Main, to step Curation: 002717
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on immunosuppressive therapy.</title>
<author><name sortKey="Singer, N G" sort="Singer, N G" uniqKey="Singer N" first="N G" last="Singer">N G Singer</name>
<affiliation wicri:level="2"><nlm:affiliation>536 RB & C, Division of Pediatric Immunology Allergy and Rheumatology, Cleveland, OH 44106, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>536 RB & C, Division of Pediatric Immunology Allergy and Rheumatology, Cleveland, OH 44106</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mccune, W J" sort="Mccune, W J" uniqKey="Mccune W" first="W J" last="Mccune">W J Mccune</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9608317</idno>
<idno type="pmid">9608317</idno>
<idno type="doi">10.1097/00002281-199805000-00003</idno>
<idno type="wicri:Area/PubMed/Corpus">000502</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000502</idno>
<idno type="wicri:Area/PubMed/Curation">000502</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000502</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000472</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000472</idno>
<idno type="wicri:Area/Ncbi/Merge">001179</idno>
<idno type="wicri:Area/Ncbi/Curation">001179</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001179</idno>
<idno type="wicri:doubleKey">1040-8711:1998:Singer N:update:on:immunosuppressive</idno>
<idno type="wicri:Area/Main/Merge">002755</idno>
<idno type="wicri:Area/Main/Curation">002717</idno>
<idno type="wicri:Area/Main/Exploration">002717</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Update on immunosuppressive therapy.</title>
<author><name sortKey="Singer, N G" sort="Singer, N G" uniqKey="Singer N" first="N G" last="Singer">N G Singer</name>
<affiliation wicri:level="2"><nlm:affiliation>536 RB & C, Division of Pediatric Immunology Allergy and Rheumatology, Cleveland, OH 44106, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>536 RB & C, Division of Pediatric Immunology Allergy and Rheumatology, Cleveland, OH 44106</wicri:regionArea>
<placeName><region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mccune, W J" sort="Mccune, W J" uniqKey="Mccune W" first="W J" last="Mccune">W J Mccune</name>
</author>
</analytic>
<series><title level="j">Current opinion in rheumatology</title>
<idno type="ISSN">1040-8711</idno>
<imprint><date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Arthritis, Juvenile (drug therapy)</term>
<term>Azathioprine (adverse effects)</term>
<term>Azathioprine (therapeutic use)</term>
<term>Behcet Syndrome (drug therapy)</term>
<term>Child</term>
<term>Cladribine (therapeutic use)</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Cyclophosphamide (therapeutic use)</term>
<term>Cyclosporine (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Granulomatosis with Polyangiitis (drug therapy)</term>
<term>Humans</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunosuppressive Agents (administration & dosage)</term>
<term>Immunosuppressive Agents (adverse effects)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Liver (drug effects)</term>
<term>Liver (injuries)</term>
<term>Lung (drug effects)</term>
<term>Lung Injury</term>
<term>Lupus Erythematosus, Systemic (drug therapy)</term>
<term>Methotrexate (administration & dosage)</term>
<term>Methotrexate (adverse effects)</term>
<term>Methotrexate (therapeutic use)</term>
<term>Pemphigoid, Benign Mucous Membrane (drug therapy)</term>
<term>Retina (drug effects)</term>
<term>Tacrolimus (therapeutic use)</term>
<term>Thalidomide (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Arthrite juvénile (traitement médicamenteux)</term>
<term>Association de médicaments</term>
<term>Azathioprine (effets indésirables)</term>
<term>Azathioprine (usage thérapeutique)</term>
<term>Chloro-2 désoxyadénosine (usage thérapeutique)</term>
<term>Ciclosporine (usage thérapeutique)</term>
<term>Cyclophosphamide (administration et posologie)</term>
<term>Cyclophosphamide (usage thérapeutique)</term>
<term>Enfant</term>
<term>Foie ()</term>
<term>Foie (traumatismes)</term>
<term>Granulomatose avec polyangéite (traitement médicamenteux)</term>
<term>Humains</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunosuppresseurs (administration et posologie)</term>
<term>Immunosuppresseurs (effets indésirables)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Lupus érythémateux disséminé (traitement médicamenteux)</term>
<term>Lésion pulmonaire</term>
<term>Maladie de Behçet (traitement médicamenteux)</term>
<term>Méthotrexate (administration et posologie)</term>
<term>Méthotrexate (effets indésirables)</term>
<term>Méthotrexate (usage thérapeutique)</term>
<term>Pemphigoïde bénigne des muqueuses (traitement médicamenteux)</term>
<term>Poumon ()</term>
<term>Rétine ()</term>
<term>Tacrolimus (usage thérapeutique)</term>
<term>Thalidomide (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cyclophosphamide</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Methotrexate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Azathioprine</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Methotrexate</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cyclophosphamide</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Méthotrexate</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Liver</term>
<term>Lung</term>
<term>Retina</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Juvenile</term>
<term>Behcet Syndrome</term>
<term>Granulomatosis with Polyangiitis</term>
<term>Lupus Erythematosus, Systemic</term>
<term>Pemphigoid, Benign Mucous Membrane</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Azathioprine</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Méthotrexate</term>
</keywords>
<keywords scheme="MESH" qualifier="injuries" xml:lang="en"><term>Liver</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azathioprine</term>
<term>Cladribine</term>
<term>Cyclophosphamide</term>
<term>Cyclosporine</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Methotrexate</term>
<term>Tacrolimus</term>
<term>Thalidomide</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite juvénile</term>
<term>Granulomatose avec polyangéite</term>
<term>Lupus érythémateux disséminé</term>
<term>Maladie de Behçet</term>
<term>Pemphigoïde bénigne des muqueuses</term>
</keywords>
<keywords scheme="MESH" qualifier="traumatismes" xml:lang="fr"><term>Foie</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Azathioprine</term>
<term>Chloro-2 désoxyadénosine</term>
<term>Ciclosporine</term>
<term>Cyclophosphamide</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Méthotrexate</term>
<term>Tacrolimus</term>
<term>Thalidomide</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Child</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Lung Injury</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Association de médicaments</term>
<term>Enfant</term>
<term>Foie</term>
<term>Humains</term>
<term>Lésion pulmonaire</term>
<term>Poumon</term>
<term>Rétine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In this review we summarize selected articles that have been published about immunosuppressive agents in the past year. These studies fall into three major categories: 1) use of pulse cyclophosphamide in autoimmune diseases other than systemic lupus erythematosus; 2) use of newer immunosuppressive agents such as cyclosporine and FK506 in a variety of rheumatic diseases; and 3) toxicity.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Ohio</li>
</region>
</list>
<tree><noCountry><name sortKey="Mccune, W J" sort="Mccune, W J" uniqKey="Mccune W" first="W J" last="Mccune">W J Mccune</name>
</noCountry>
<country name="États-Unis"><region name="Ohio"><name sortKey="Singer, N G" sort="Singer, N G" uniqKey="Singer N" first="N G" last="Singer">N G Singer</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002717 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002717 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:9608317 |texte= Update on immunosuppressive therapy. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9608317" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |